Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sirolimus: its role in nephrology.

Vincent Ws Lee1, Jeremy R Chapman

  • 1Department of Renal Medicine, Westmead Hospital, New South Wales, Australia. Vincent_Lee@wmi.usyd.edu.au

Nephrology (Carlton, Vic.)
|December 16, 2005
PubMed
Summary

Sirolimus (SRL), a novel immunosuppressant, preserves renal function and improves graft survival in transplantation by inhibiting T cell proliferation via mTOR. Its potential role in managing chronic allograft nephropathy and impacting cancer warrants further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deceased Organ Donation and Transplantation in LIMC: A Meeting Report.

Transplantation·2026
Same author

Longitudinal Assessment of Health-Related Quality of Life in Adults with CKD.

Kidney360·2025
Same author

Economic Evaluation of System-Wide Implementation of Kidney Supportive Care.

Kidney international reports·2025
Same author

A Global Survey of Self-Reported Cancer Screening Practices by Health Professionals for Kidney Transplant Candidates and Recipients.

Transplant international : official journal of the European Society for Organ Transplantation·2025
Same author

Organ Transplantation in India: NOT for the Common Good.

Transplantation·2024
Same author

Surveillance for donor-derived infections in Australia.

Transplant infectious disease : an official journal of the Transplantation Society·2024

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Sirolimus (SRL) is a novel immunosuppressant gaining attention in organ transplantation.
  • It represents a new drug class with a unique mechanism of action.
  • SRL targets the FK binding protein (FKBP) and the protein kinase mTOR pathway.

Purpose of the Study:

  • To elucidate the mechanism of action of Sirolimus (SRL).
  • To highlight the advantages of SRL over existing immunosuppressants.
  • To explore the potential applications of SRL in transplantation, including chronic allograft nephropathy and cancer prognosis.

Main Methods:

  • Binding of SRL to FKBP forms a complex that inhibits mTOR.
  • mTOR inhibition leads to cell cycle arrest in the G1 phase.

Related Experiment Videos

  • SRL blocks interleukin-2 (IL-2)-induced T cell proliferation.

    • Main Results:

    • SRL preserves renal function and pathology.
    • Excellent rejection-free graft survival rates are achieved with SRL.
    • SRL may serve as a calcineurin inhibitor replacement for chronic allograft nephropathy.

    Conclusions:

    • Sirolimus (SRL) offers a promising alternative immunosuppressive strategy.
    • Its ability to preserve renal function and enhance graft survival is a key advantage.
    • Further research is needed to optimize SRL dosage and timing for minimizing side effects and evaluating its impact on cancer.